Correlation Between Risk of Febrile Neutropenia Based on Rondinelli Score with Clinical Outcomes in Acute Lymphoblastic Leukemia Patients
Downloads
Febrile neutropenia (FN) is the most severe complication in patients with blood cancer and chemotherapy. Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children and the most common cause of febrile neutropenia. The low number of neutrophils in ALL patients due to lymphoblast cancer cells and the toxicity of chemotherapy makes patients susceptible to infection which, if not treated immediately, can lead to death. Early risk assessment for infectious complications in FN patients is needed to increase clinician awareness in high-risk patients and eliminate unnecessary therapy for low-risk patients. The Rondinelli scoring system is a reasonably good instrument for predicting severe infectious complications in pediatric patients with ALL who have febrile neutropenia. This study aims to determine the relationship between the risk category for febrile neutropenia (FN) based on the Rondinelli score with clinical outcomes in FN patients with acute lymphoblastic leukemia (ALL) in the Hematology-Oncology division of the child health department of RSUD Dr. Soetomo. This analytic observational study used secondary data FN patients with acute lymphoblastic leukemia (ALL) implementing a total sampling. From 30 samples of pediatric ALL patients with febrile neutropenia at Dr. Soetomo Hospital for June 2018-June 2020 it was found 17 patients (56.7%) had a moderate risk score category, and 13 others were in a low-risk category (43.3 %). Patients were dominated by moderate and severe severity of neutropenia respectively, 43.3%, had neutropenia for 1-7 days (50%), fever less than seven days (66.7%), had a length of stay of 8-14 days, and 15-30 days 33.3% each. Conclusion from this research is that there was a signiï¬ cant relationship between the Rondinelli score category in pediatric ALL patients with FN with the severity of neutropenia p=0.037; R=0.383), duration of neutropenia (p=0.021; R=0.420), duration of fever (p=0.000; R=0.618), and length of stay (p-value 0.005; R=0.496).
Adrieanta A, Windiastuti E, Handryastuti S. Etiologi demam neutropenia pada anak dengan keganasan dan penggunaan skor klasiï¬ kasi Rondinelli. Sari Pediatri. 2016 Nov 9;16(4):229-35.
Rasmy A, Amal A, Fotih S, Selwi WJ. Febrile neutropenia in cancer patient: epidemiology, microbiology, pathophysiology and management. J Cancer Prev Curr Res. 2016;5(3):00165.
Widiaskara IM, Permono B, Ugrasena ID, Ratwita M. Luaran pengobatan fase induksi pasien leukemia limfoblastik akut pada anak di rumah sakit umum Dr. Soetomo Surabaya. Sari Pediatri. 2016 Nov 23;12(2):128-34.
Nugraheni AY, Rahardiani SS. Evaluation of antibiotic in acute lymphoblastic leukemia patients with febrile neutropenia. Jurnal Farmasi Sains dan Praktis. 2020 Apr 28;6(1):19-30.
Nugroho S. Parameter bakteremia pada anak dengan keganasan dan demam neutropenia. Jurnal Kedokteran Brawijaya. 2013 Mar 10;26(2):113-6.
Haeusler GM, Thursky KA, Slavin MA, Babl FE, Lourenco RDA, Allaway Z, et al. Risk stratiï¬ cation in children with cancer and febrile neutropenia: A national, prospective, multicentre validation of nine clinical decision rules. EClinicalMedicine 2020 Jan 7;18:100220.
Hidayat R, Gatot D, Djer MM. Validasi sistem skoring Rondinelli untuk mendeteksi komplikasi infeksi berat pada pasien leukemia limfoblastik akut L1 dengan demam neutropenia selama kemoterapi fase induksi. Sari Pediatri. 2016 Nov 9;15(5):325-1.
Rondinelli PI, Ribeiro KD, de Camargo B. A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. J Pediatr Hematol Oncol. 2006 Oct 1;28(10):665-70.
Syamsuri I. Hubungan karakteristik dan gambaran laboratorium terhadap luaran pada anak demam neutropenia dan leukemia limfoblastik akut (LLA) di divisi hematologi–onkologi departemen ilmu kesehatan anak RSUD Dr. Soetomo Surabaya periode Januari 2017–Juni 2017 [thesis]. Surabaya: Universitas Airlangga; 2017.
Nursyirwan SR, Windiastuti E. Kejadian demam neutropenia pada anak dengan keganasan. Sari Pediatri. 2018 Mar 1;19(4):220-5.
Yu MG, Villalobos RE, Juan-Bartolome M, Berba RP. Predictors of outcome and severity in adult Filipino patients with febrile neutropenia. Advances in hematology. 2015 Sep 3;2015.
Badr M, Hassan T, Sakr H, Karam N, Rahman DA, Shahbah D, et al. Chemotherapy-induced neutropenia among pediatric cancer patients in Egypt: Risks and consequences. Mol Clin Oncol. 2016 Sep 1;5(3):300-6.
Badiei Z, Khalesi M, Alami MH, Kianifar HR, Banihashem A, Farhangi H, et al. Risk factors associated with life-threatening infections in children with febrile neutropenia: a data mining approach. J Pediatr Hematol Oncol. 2011 Jan 1;33(1):e9-12.
Coyne CJ, Le V, Brennan JJ, Castillo EM, Shatsky RA, Ferran K, et al. Application of the MASCC and CISNE risk-stratiï¬ cation scores to identify low-risk febrile neutropenic patients in the emergency department. Ann Emerg Med. 2017 Jun 1;69(6):755-64.
Kholis FN. Penilaian risiko infeksi dengan skor MASCC pada penderita demam neutropenia di rumah sakit dr. kariadi dan Telogorejo Semarang. Media Medika Muda. 2018 May 4;2(1).
Hall JE. Guyton and Hall textbook of medical physiology. 13th ed. Philadelphia (PA): Elsevier, Inc.; 2016
Miedema KG, Tissing WJ, Abbink FC, Ball LM, Michiels EM, van Vliet MJ, et al. Risk-adapted approach for fever and neutropenia in paediatric cancer patients–a national multicentre study. Eur J Cancer. 2016 Jan 1;53:16-24.
Kebudi R, Kizilocak H. Febrile neutropenia in children with cancer: approach to diagnosis and treatment. Curr Pediatr Rev. 2018 Aug 1;14(3):204-9.
Link H, Böhme A, Cornely OA, Höff ken K, Kellner O, Kern WV, et al. Antimicrobial therapy of unexplained fever in neutropenic patients. Ann Hematol. 2003 Oct;82(2):S105-17.
Hazan G, Ben-Shimol S, Fruchtman Y, Abu-Quider A, Kapelushnik J, Moser A, et al. Clinical and laboratory parameter dynamics as markers of bloodstream infections in pediatric oncology patients with fever and neutropenia. J Pediatr Hematol Oncol. 2014 Jul 1;36(5):e275-9.
Reinecke J, Lowas S, Snowden J, Neemann K. Blood stream infections and antibiotic utilization in pediatric leukemia patients with febrile neutropenia. Journal of pediatric hematology/oncology. 2019 May 1;41(4):251-5.
Lathia N, Mittmann N, DeAngelis C, Knowles S, Cheung M, Pilotis E, et al. Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer. 2010 Feb 1;116(3):742-8.
Alexander SW, Wade KC, Hibberd PL, Parsons SK. Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol. 2002 Jan 1;24(1):38-42.
Swati M, Gita N, Sujata B, Farah J, Preeti M. Microbial etiology of febrile neutropenia. Indian Journal of Hematology and Blood Transfusion. 2010 Jun;26(2):49-55.
Avilés-Robles M, Ojha RP, González M, OjedaDiezbarroso K, Dorantes-Acosta E, Jackson BE, Johnson KM, Caniza MA. Bloodstream infections and inpatient length of stay among pediatric cancer patients with febrile neutropenia in Mexico City. American journal of infection control. 2014 Nov 1;42(11):1235-7.
Das A, Trehan A, Bansal D. Risk factors for microbiologically-documented infections, mortality and prolonged hospital stay in children with febrile neutropenia. Indian pediatrics. 2018 Oct;55(10):85964.
Allareddy V, Rampa S, Allareddy V. Hospital charges and length of stay associated with septicemia among children hospitalized for leukemia treatment in the United States. World Journal of Pediatrics. 2012 Aug;8(3):222-8.
Copyright (c) 2022 Indonesian Journal of Tropical and Infectious Disease
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Indonesian Journal of Tropical and Infectious Disease (IJTID) is a scientific peer-reviewed journal freely available to be accessed, downloaded, and used for research. All articles published in the IJTID are licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which is under the following terms:
Attribution ” You must give appropriate credit, link to the license, and indicate if changes were made. You may do so reasonably, but not in any way that suggests the licensor endorses you or your use.
NonCommercial ” You may not use the material for commercial purposes.
ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
